Recent developments on ketolides and macrolides.
Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773, for the treatment of community-acquired bacterial infections caused by both macrolide- and beta-lactam-susceptible and -resistant S. pneumoniae, gram negative bacteria, and intracellular atypical pathogens. The discovery of ketolides has rekindled interest in macrolides, and recent efforts have also led to a novel class of 4''-carbamates with activity against macrolide-resistant organisms. This review is an account of recent developments on ketolides and macrolides in terms of both chemistry and antibacterial activity.
Wu
Y J
YJ
Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, USA. Yong-Jin.Wu@BMS.com
Su
W G
WG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology*; D002219:Carbamates / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D048628:Ketolides; D007659:Ketones / Q000737:chemistry; D018942:Macrolides / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; C447959:CP-544372; D002219:Carbamates; D048628:Ketolides; D007659:Ketones; D018942:Macrolides; D004917:Erythromycin; C405499:cethromycin; C106791:telithromycin